Pharmaceuticals, Biotechnology & Life Sciences

Roche’s new CE‑marked Elecsys ApoE4 blood test offers rapid, highly accurate genetic risk for Alzheimer’s, fitting seamlessly into existing Elecsys platforms and paving the way for personalized, cost‑effective care.

Japanese pharma firms like Daiichi Sankyo can boost margins 10%+ with AI, while the Nikkei’s modest rally fuels capital for healthcare’s digital shift—balancing tech costs, reimbursements, and quality outcomes.

Waters Corp’s latest filings reveal a smart senior‑notes debt program, S‑3ASR flexibility, and a SpinCo acquisition to boost high‑throughput LC tools for pharma R&D.

Discover how Sartorius AG’s new Eveo Cell Therapy Platform and focus on high‑margin single‑use systems will drive biopharma growth, cost savings, and EBITDA gains.

Explore how Bayer AG’s specialty implant strategy drives 13 % core sales growth and high‑teens EBITDA, backed by custom‑fit solutions, global expansion, and disciplined cost control.

Pfizer CEO Albert Bourla boosts his stake by converting phantom stock units into shares, showing how pharma leaders align incentives with shareholder value.

Roche’s Elecsys ApoE4 immunoassay, now CE‑marked, delivers a 99 % accurate, rapid plasma test for Alzheimer’s‑risk ApoE4 carriers—streamlining diagnosis and guiding precision therapy.

Explore how U.S. investors’ shift to European equities fuels German diagnostics, focusing on reimbursement, R&D, and operational hurdles shaping long‑term value.

Explore Haleon’s 2025 annual report: modest growth, margin pressures, strategic brand realignment, and new digital health plans poised to shape 2026.

MTI’s 20% stock drop reveals margin tightening, lagging R&D, and regulatory hurdles—yet offers upside in digital analytics, ESG, and emerging‑market growth.